Deal title Receiving grant Awarding grant Grant amount ($M) Date

October

NINDS to award Adynxx funding to develop AYX-2 to treat chronic pain Adynxx Inc National Institute of Neurological Disorders and Stroke 0.60 10/2/19
NIAID to award BlueWillow Biologics funding to develop nanoemulsion adjuvant-based vaccine for peanut allergy BlueWillow Biologics National Institute of Allergy and Infectious Diseases 3.20 10/1/19
Federal Ministry for Economic Affairs and Energy to award Ethris funding to develop SNIM RNA therapeutics for PCD Ethris GmbH German Federal Ministry for Economic Affairs and Energy Payment unspecified 10/1/19
BARDA to fund Sabin Vaccine Institute for the development of two filovirus vaccines Sabin Vaccine Institute U.S. Department of Health and Human Services 128.00 10/1/19
NINDS to award Adynxx funding to develop AYX-2 to treat chronic pain Adynxx Inc National Institute of Neurological Disorders and Stroke 0.60 10/2/19
NIDA and NINDS to award Peptide Logic funding to develop non-addictive, peripherally restricted and long-acting somatostatin receptor 4 agonists for the treatment of moderate to severe pain, reducing the need for opioid use Peptide Logic Inc. National Institute of Neurological Disorders and Stroke Payment unspecified 10/4/19
CQDM to award UQAM funding for development of targeted oncology platform in triple-negative breast cancer Universite du Quebec a Montreal CQDM 1.70 10/4/19
FDA to award TTT funding to support phase I study on episcleral topotecan for retinoblastoma Targeted Therapy Technologies LLC Food and Drug Administration 0.66 10/8/19
NIH HEAL Initiative to award NeuroCycle Therapeutics funding for the development of non-addictive, non-opioid therapy against chronic musculoskeletal pain NeuroCycle Therapeutics Inc National Institutes of Health Payment unspecified 10/1/19
FDA to award a grant to Cumberland to conduct phase 2 study of oral ifetroban for cardiomyopathy with DMD Cumberland Pharmaceuticals Inc Food and Drug Administration 1.00 10/8/19
FDA to award University of Texas funding to support phase I/II study on imipridone for acute myeloid leukemia MD Anderson Cancer Center Food and Drug Administration 1.00 10/8/19
FDA to award Cincinnati Children's Hospital Medical Center funding to develop drugs against cancers Cincinnati Children's Hospital Medical Center Food and Drug Administration 2.45 10/8/19
FDA to award MGH funding to support phase II study on anti-PD1 therapy for HPV-associated recurrent respiratory papillomatosis Massachusetts General Hospital Food and Drug Administration 1.00 10/8/19
NINDS to award Fast-Track SBIR Grant to Expesicor to develop KaL model against neurodegeneration and epilepsy Expesicor LLC National Institute of Neurological Disorders and Stroke 1.40 10/8/19
CQDM to award UQAM funding for development of Theratechnologies' TH-1902 (docetaxel/sortilin receptor modulator conjugate) in triple-negative breast cancer Universite du Quebec a Montreal CQDM 1.70 10/4/19
Gateway for Cancer Research to award City of Hope funding to conduct phase I clinical trial of MB-101 against recurrent malignant glioma City of Hope Gateway for Cancer Research 0.80 10/10/19
NIH to award Aruna Bio funding for the preclinical development of AB-126 against acute ischemic stroke Aruna Bio Inc. National Institutes of Health Payment unspecified 10/10/19
Gateway for Cancer Research to award City of Hope funding to conduct phase I clinical trial of MB-101 against recurrent malignant glioma City of Hope Gateway for Cancer Research 0.80 10/10/19
NIH to award Oligomerix funding for the development of small-molecule inhibitors of tau oligomer formation to treat Alzheimer's disease and related neurodegenerative diseases Oligomerix Inc. National Institutes of Health Payment unspecified 10/10/19
NMSS to award Clene Nanomedicine funding to develop and determine the effects of CNM-Au8 on biological markers in MS Clene Nanomedicine Inc National Multiple Sclerosis Society 0.34 10/14/19
North Carolina Biotechnology Center to award Arrevu funding to complete supplemental studies and to design a phase II/III clinical trial of sodium fusidate to treat cystic fibrosis Arrevus Inc North Carolina Biotechnology Center 0.25 10/15/19
AusIndustry to fund Botanix to discover cannabidiol analogues Botanix Pharmaceuticals Ltd AusIndustry 0.05 10/15/19
Cystic Fibrosis Foundation to award Enterprise Therapeutics funding for the development of ETD-002 against cystic fibrosis Enterprise Therapeutics Ltd. Cystic Fibrosis Foundation Payment unspecified 10/15/19
Plus Therapeutics to receive reimbursement from BARDA related to the contract for development of cell therapy against thermal burns combined with radiation injury Plus Therapeutics Inc. Biomedical Advanced Research and Development Authority Payment unspecified 10/15/19
Immutep R&D tax incentive payment in cash from the French government to support ongoing and planned global clinical development of eftilagimod alpha and preclinical development of IMP-761 Immutep Ltd. French government Payment unspecified 10/10/19
NIDA to award Delpor funding to develop once-yearly Naltrexone for relapse to opioid dependence Delpor Inc National Institute on Drug Abuse 5.70 10/10/19
NIAAA to award Amygdala Neurosciences funding to test the toxicity of ANS-6637 against opioid use disorder and smoking cessation in rats and monkeys Amygdala Neurosciences Inc National Institute on Alcohol Abuse and Alcoholism Payment unspecified 10/21/19
Armata Pharmaceuticals received a research and development tax incentive cash rebate from the Australian Tax Office for development of novel bacteriophage therapies Armata Pharmaceuticals Inc. Australian Government Payment unspecified 10/21/19
Phagomed Biopharma to award Austrian Research Promotion Agency funding for development of drug candidate against bacterial vaginosis Phagomed Biopharma GmbH Austrian Research Promotion Agency Payment unspecified 10/22/19
National Cancer Institute to award Envisagenics funding to discover targets for immuno-oncology products using Splicecore drug discovery platform Envisagenics Inc. National Cancer Institute Payment unspecified 10/23/19
NCI to award Isoplexis funding for the advancement of intracellular proteomic pathway targeting solutions for single tumor cell analyses Isoplexis Inc. National Cancer Institute Payment unspecified 10/23/19
FFG to award Phagomed funding to develop endolysin for bacterial vaginosis PhagoMed Biopharma GmbH The Austrian Research Promotion Agency FFG 1.11 10/22/19
CARB-X to fund BioVersys to support the development of anti-virulence small molecule drugs BioVersys AG Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator 8.92 10/29/19
Bill & Melinda to award BCD funding to develop oligosaccharides for human health and nutrition applications BCD Bioscience Bill & Melinda Gates Foundation Payment unspecified 10/29/19
Bill & Melinda Gates Foundation to award Enesi Pharma funding to develop and evaluate ImplaVax technology against Measles and Rubella Enesi Pharma Bill & Melinda Gates Foundation Payment unspecified 10/29/19
NKF to award Beth Israel Deaconess Medical Center to study the role of RNA Editing in APOL1 inhibition for kidney disease Beth Israel Deaconess Medical Center National Kidney Foundation Payment unspecified 10/29/19
Cystic Fibrosis Foundation to award Laurent Pharmaceuticals additional funding for APPLAUD phase II study evaluating LAU-7b in adult patients with cystic fibrosis Laurent Pharmaceuticals Inc. Cystic Fibrosis Foundation Payment unspecified 10/31/19
Federal Ministry to award funding to Charite Universitaetsmedizin to develop preprodynorphin gene therapy for epilepsy Charite Universitaetsmedizin Berlin Federal Ministry of Education and Research Service 3.67 10/30/19
UK Government to invest in GARDP to develop zoliflodacin against gonorrhoea and other treatments for bacterial infection Global Antibiotic Research and Development Partnership UK Government 4.31 10/28/19
NINDS to award Eicosis funding for the development of EC-5026 against diabetic neuropathic pain Eicosis LLC National Cancer Institute Payment unspecified 10/30/19
AMED to award Okayama University grant to conduct preclinical studies for OBP-702 against cancer like osteosarcoma and pancreatic ductal adenocarcinoma Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Japan Agency for Medical Research and Development Payment unspecified 10/30/19

No Comments